ASIC3 and plasma cell myeloma: Interestingly, a selective ASIC3 antagonist, APETx2, was able to markedly reduce bone pain in a murine intratibial multiple myeloma model and decreased excitability of DRG neurons cocultured with human multiple myeloma cells,36 providing functional evidence for the role of ASIC3.